MicroRNAs, T-cell Immunity and Immunotherapy
Bikash R Giri,Guofeng Cheng
DOI: https://doi.org/10.4155/fmc-2019-0145
2019-01-01
Future Medicinal Chemistry
Abstract:Future Medicinal ChemistryVol. 11, No. 16 CommentaryMicroRNAs, T-cell immunity and immunotherapyBikash R Giri & Guofeng ChengBikash R GiriKey Laboratory of Animal Parasitology, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, 518 Ziyue Road, 200241 Shanghai, ChinaSearch for more papers by this author & Guofeng Cheng*Author for correspondence: Tel.: +86 213 429 3659; Fax: +86 215 408 1818; E-mail Address: cheng_guofeng@yahoo.comKey Laboratory of Animal Parasitology, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Ministry of Agriculture, 518 Ziyue Road, 200241 Shanghai, ChinaSearch for more papers by this authorPublished Online:20 Sep 2019https://doi.org/10.4155/fmc-2019-0145AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancercell-mediated immunityimmunotherapyinfectious diseasesmicroRNAsT cellsReferences1. Podshivalova K, Salomon DR. MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development. Crit. Rev. Immunol. 33(5), 435–476 (2013).Crossref, Medline, CAS, Google Scholar2. Jeker LT, Bluestone JA. MicroRNA regulation of T-cell differentiation and function. Immunol. Rev. 253(1), 65–81 (2013).Crossref, Medline, Google Scholar3. Giri BR, Mahato RI, Cheng G. Roles of microRNAs in T cell immunity: implications for strategy development against infectious diseases. Med. Res. Rev. 39(2), 706–732 (2019).Crossref, Medline, Google Scholar4. Sonkoly E, Janson P, Majuri ML et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J. Allergy Clin. Immunol. 126(3), 581–589.e581–520 (2010).Crossref, Medline, Google Scholar5. Landgraf P, Rusu M, Sheridan R et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129(7), 1401–1414 (2007).Crossref, Medline, CAS, Google Scholar6. Steiner DF, Thomas MF, Hu JK et al. MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. Immunity 35(2), 169–181 (2011).Crossref, Medline, CAS, Google Scholar7. Sawant DV, Wu H, Kaplan MH, Dent AL. The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol. Immunol. 54(3-4), 435–442 (2013).Crossref, Medline, CAS, Google Scholar8. Liu S-Q, Jiang S, Li C, Zhang B, Li Q-J. miR-17-92 cluster targets phosphatase and tensin homology and Ikaros family zinc finger 4 to promote TH17-mediated inflammation. J. Biol. Chem. 289(18), 12446–12456 (2014).Crossref, Medline, CAS, Google Scholar9. Jiang S, Li C, Olive V et al. Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 118(20), 5487–5497 (2011).Crossref, Medline, CAS, Google Scholar10. Liu C, Iqbal J, Teruya-Feldstein J et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood 122(12), 2083–2092 (2013).Crossref, Medline, CAS, Google Scholar11. Kopp KL, Ralfkiaer U, Gjerdrum LM et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 12(12), 1939–1947 (2013).Crossref, Medline, CAS, Google Scholar12. Wei SC, Levine JH, Cogdill AP et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6), 1120.e1117–1133.e1117 (2017).Crossref, Google Scholar13. Li L, Lu S, Liang X et al. gammadeltaTDEs: an efficient delivery system for miR-138 with anti-tumoral and immunostimulatory roles on oral squamous cell carcinoma. Mol. Ther. Nucleic Acids 14, 101–113 (2019).Crossref, Medline, CAS, Google Scholar14. Huang Q, Xia J, Wang L et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol. 11(1), 58 (2018).Crossref, Medline, Google Scholar15. Ohno M, Ohkuri T, Kosaka A et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J. Immunother. Cancer 1, 21 (2013).Crossref, Medline, Google Scholar16. Pandey RK, Sundar S, Prajapati VK. Differential expression of miRNA regulates T cell differentiation and plasticity during visceral Leishmaniasis infection. Front. Microbiol. 7, 206 (2016).Crossref, Medline, Google Scholar17. El-Assaad F, Hempel C, Combes V et al. Differential MicroRNA expression in experimental cerebral and noncerebral malaria. Infect. Immun. 79(6), 2379–2384 (2011).Crossref, Medline, CAS, Google Scholar18. Swaminathan S, Suzuki K, Seddiki N et al. Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J. Immunol. 188(12), 6238–6246 (2012).Crossref, Medline, CAS, Google Scholar19. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685–1694 (2013).Crossref, Medline, CAS, Google Scholar20. Seto AG, Beatty X, Lynch JM et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183(3), 428–444 (2018).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByThe Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors25 April 2020 | Biomolecules, Vol. 10, No. 5 Vol. 11, No. 16 Follow us on social media for the latest updates Metrics Downloaded 111 times History Received 9 May 2019 Accepted 23 May 2019 Published online 20 September 2019 Published in print August 2019 Information© 2019 Newlands PressKeywordscancercell-mediated immunityimmunotherapyinfectious diseasesmicroRNAsT cellsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download